



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-
1450, ON March 28, 2006

Audrey Boyd
March 28, 2006
DATE

Attorney Docket No. P51327

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thompson et al. March 28, 2006
Serial No.: 10/508,791 Group Art Unit No.: 1621
Filed: September 22, 2004 Examiner: S. Kumar
For: AMIDE COMPOUNDS AND METHODS OF USING THE SAME

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER
37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

Kathryn L. Sieburth

Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090



Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P51327	SERIAL NO. 10/508,791
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Thompson et al.	
		FILING DATE September 22, 2004	GROUP 1621

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US20050131014A1	6/16/05	Collini et al.	514	311	
	US20050036992A1	2/17/05	Saez et al.	424	93.21	
	US20050107444A1	5/19/05	Thompson et al.	514	345	
	US20030229062A1	12/11/03	Schwartz et al.	514	177	
	US20050113580A1	5/26/05	Thompson et al.	546	268.1	
	US20050171084A1	8/4/05	Cairns et al.	514	210.21	
	US20030153541A1	8/14/03	Dudley et al.	514	171	
	US20030229062A1	12/11/03	Schwartz et al.	514	177	
	US20040072868A1	4/15/04	Collins et al.	514	318	
	US20030162758A1	8/28/03	Schwartz et al.	514	172	
	US20040266663A1	12/30/04	Schwartz et al.	514	2	
	US20050282750A1	12/22/05	Schwartz et al.	514	12	
	US20050282908A1	12/22/05	Collins et al.	514	620	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 06/004030 A1 Abstract only	1/13/06	PCT				
	WO 06/000577 A2	1/5/06	PCT				
	WO 06/000576 A2	1/5/06	PCT				
	WO 05/055998 A1	6/23/05	PCT				
	WO 05/013946 A2	2/17/05	PCT				
	WO 05/009383 A2	2/3/05	PCT				
	WO 04/110375 A2	12/23/04	PCT				
	WO 04/110368 A2	12/23/04	PCT				
	WO 04/058819 A2	7/15/04	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Grefhorst et al. <i>Am. J. Physiol. Endocrinol. Metab.</i> , 289: E829-E838 (2005).
	Groot et al. <i>J. Lipid Res.</i> , 46: 2182-2191 (2005).
	Jaye et al. <i>J. Med. Chem.</i> , 48: 5419-5422 (2005).
	Ogawa et al. <i>Circ. Res.</i> , 96: e59-e67 (2005).
	Quinet et al. <i>J. Lipid Res.</i> , 45: 1929-1942 (2004).
	Miao et al. <i>J. Lipid Res.</i> , 45: 1410-1417 (2004).
	Schmuth et al. <i>J. Invest. Dermatol.</i> 123: 41-48 (2004).
	Farnegardh et al. <i>J. Biol. Chem.</i> , 278(40): 38821-38828 (2003).
	Wang et al. <i>J. Molec. Graphics and Modelling</i> , 22: 173-181 (2003).
	Fowler et al. <i>J. Invest. Dermatol.</i> , 120: 246-255 (2003).
	Joseph et al. <i>PNAS USA</i> , 99(11): 7604-7609 (2002).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P51327	SERIAL NO. 10/508,791
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Thompson et al.	
		FILING DATE September 22, 2004	GROUP 1621

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Fluhr et al. <i>J. Invest. Dermatol.</i> , <u>125</u> : 1206-1214 (2005).
	Naik et al. <i>Circulation</i> , <u>113</u> : 90-97 (2006).
	Kruit et al. <i>Gastroenterology</i> , <u>128</u> : 147-156 (2005).
	Laffitte et al. <i>PNAS USA</i> , <u>100</u> (9): 5419-5424 (2003).
	Castrillo et al. <i>J. Biol. Chem.</i> , <u>278</u> (12): 10443-10449 (2003).
	Laffitte et al. <i>Mol. & Cell. Biol.</i> , <u>23</u> (6): 2182-2191 (2003).
	Collins et al. <i>J. Med. Chem.</i> , <u>45</u> : 1963-1966 (2002).
	Terasaka et al. <i>FEBS Journal</i> , <u>272</u> : 1546-1556 (2005).
	Collins et al. <i>Abstracts of Papers, 230th ACS National Meeting, Washington, DC. August 28-September 1, 2005. MEDI-237. Publisher: American Chemical Society, Washington, DC.</i>
	Rao et al. <i>Abstracts of Papers, 229th ACS National Meeting, San Diego, CA. March 13-17, 2005. COMP-258. Publisher: American Chemical Society, Washington, DC.</i>
	Jon L. Collins. <i>Abstracts of Papers, 225th ACS National Meeting, New Orleans, LA. March 23-27, 2003. MEDI-152. Publisher: American Chemical Society, Washington, DC.</i>
	Collins et al. <i>Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL. April 7-11, 2002. MEDI-123. Publisher: American Chemical Society, Washington, DC.</i>

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.